
Noted Vaccine Researcher and Leader Kate O'Brien Awarded Sabin's Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
O'Brien is a pioneering global health leader whose innovative work in vaccine access and policy has transformed immunization programs worldwide.
'I am honored to award the Sabin Gold Medal to Dr. O'Brien for her extensive scientific and humanitarian work, which has significantly contributed to the development, licensure, and global distribution of critical immunizations,' says Amy Finan, Sabin's chief executive officer. 'The breadth and scope of her work — in addition to her leadership in advancing the availability of vaccines for everyone, everywhere — has saved millions of lives around the world.'
O'Brien's interest in vaccines and preventable illness began during her early career as a research pediatrician in Port-au-Prince, Haiti, where almost a third of children admitted to the hospital she worked at died, often from vaccine-preventable diseases. Returning to the U.S. to pursue her infectious disease fellowship, Master of Public Health, and training as an epidemiologist, she then worked for the Johns Hopkins Center for American Indian Health and led groundbreaking clinical trials on the pneumococcal vaccine to establish the vaccine's performance and impact on both disease and on colonization to achieve both individual and population-level protection. O'Brien was appointed Director of Infectious Disease at the Center and led research on vaccine development and implementation for vaccine-preventable diseases disproportionately affecting Indigenous populations. Her work in large-scale vaccine impact studies and clinical trials has been instrumental in the licensure, introduction and global use of vaccines against pneumococcal disease, rotavirus, influenza, and respiratory syncytial virus (RSV).
.
O'Brien continued her leadership in vaccine development, access, and research in her position as the Executive Director of the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health. She has served on WHO's Strategic Advisory Group of Experts on Immunization (SAGE) and on the board of Gavi, the Vaccine Alliance, where she has influenced vaccine financing, policy development, and global immunization strategies.
In her current role as Director, Immunization, Vaccines and Biologicals for the World Health Organization (WHO), O'Brien leads the global vaccine and immunization strategy. She oversees WHO's work across the vaccine continuum by accelerating new vaccine research and development, advancing vaccine access and equity, introducing new vaccines into country programs, identifying and responding to outbreaks including as WHO's vaccine technical lead during the COVID-19 pandemic, and strengthening immunization program reach in order to maximize the impact of vaccines, even in the most fragile and vulnerable settings.
O'Brien earned her medical degree from McGill University and a Master of Public Health from Johns Hopkins University. She completed her pediatric and infectious disease training at Johns Hopkins Medical Institutions and served as an Epidemic Intelligence Service officer at the U.S. Centers for Disease Control and Prevention (CDC).
'I am deeply grateful for a career working with incredible people around the world, and through them to have life-saving impact,' says O'Brien. 'Vaccines are truly one of science's greatest achievements. It is immensely fulfilling to work on vaccines all the way from development through licensure and dissemination, and to then see them protect the lives and well-being of families. This award is a huge honor, and a tribute to those who have taught me the value of evidence-based courage.'
Sabin's Rising Star Award is intended to encourage and recognize the next generation of vaccine and immunization leaders. Mbianke is a dedicated physician and public health specialist whose work in vaccine access and strengthening health systems has made a profound impact on underserved communities. With expertise in immunization, maternal and child health, and community engagement, Mbianke has played a pivotal role in expanding vaccine coverage and improving health outcomes in Cameroon.
'With his recognized achievements in reducing maternal and child mortality by 50% in remote areas and increasing accessibility of vaccines, Dr. Mbianke is leading innovations around immunization in fragile settings,' says Finan. 'Whether he is delivering vaccines to displaced populations or creating health clinics out of village councils, his creative solutions serve as a model for those working in challenging settings and makes him a Rising Star in global health.'
As Program Country Manager for the COMBAT Project (Community-Based Tracking for Immunization) at the International Vaccine Access Center (IVAC), Mbianke leads efforts to enhance immunization delivery by improving community-based monitoring, engagement, and service delivery strategies. He also serves as Technical Advisor for the World Health Organization's 'Big Catch-Up,' a global initiative aimed at restoring vaccine coverage following pandemic-related disruptions.
Beyond his advisory roles, Mbianke is the CEO of Empower Women Foundation, where he champions maternal and child health initiatives in Cameroon, advocating for sustainable and locally driven health care solutions. His leadership extends to past roles with WHO, Gavi, USAID, and other global health organizations, where he has contributed to immunization policy formulation and innovative strategies to reach zero-dose and under-immunized children.
A graduate of Université de la Montagne Bagante (MD) and Mountain University for Sustainable Studies (MPH), Mbianke combines medical expertise with public health leadership to promote vaccine confidence and equitable access.
'This award is so meaningful,' says Mbianke. 'When you work in settings with such a high burden, sometimes you feel you are not doing enough because you want to improve as many lives as possible. But recognition like the Rising Star award really motivates you. It says you are creating an impact. You are creating a change.'
Awarded annually since 1993 and 2020 respectively, the Albert B. Sabin Gold Medal and Rising Star Award honor individuals who have made extraordinary contributions to immunization and global health. These awards commemorate the legacy of the late Dr. Albert B. Sabin, who discovered the oral polio vaccine and dedicated his life to ensuring everyone in the world had access to vaccines.
Watch the 2025 Albert B. Sabin Gold Medal and Rising Star ceremony on Sabin's YouTube channel.
About the Sabin Vaccine Institute
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X @SabinVaccine.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
22 minutes ago
- CTV News
‘Ozempic face' may be driving cosmetic surgery boom
Watch Plastic Surgeon Dr. Bob Basu on if 'Ozempic face' is a real concern and why are user seeing side-effects after weight loss.


Globe and Mail
3 hours ago
- Globe and Mail
Want Another $500 in Annual Dividend Income? Invest $6,900 in These 3 High-Yield Stocks.
Key Points Altria Group's cigarette sales are in decline, but smokeless options are picking up the slack. Healthpeak Properties is a leading healthcare-related real estate investment trust. Ares Capital is an enormous business development company with a 16-year history of steady-to-rising dividend payouts. 10 stocks we like better than Altria Group › Would your budget benefit from a significantly larger stream of passive income? There are many ways to make that happen, but I don't know of any that are easier than buying high-yield dividend stocks. Shares of Altria Group (NYSE: MO), Healthpeak Properties (NYSE: DOC), and Ares Capital (NASDAQ: ARCC) have been offering an average yield of 7.3% at recent prices. With such high yields, folks who invest $6,900 evenly among these three stocks could receive over $500 in annual dividend payments. Here's a closer look at each company to see how they could make excellent additions to an income-generating portfolio. 1. Altria Group Shares of the company that sells Marlboro brand cigarettes in the U.S. have risen about 15% over the past 12 months. Cigarette volumes are down, but investors have been encouraged by results for its smokeless-product offerings. Disposable vaporizers that deliver lots of nicotine for a fraction of the price of a pack of Marlboros have been a challenge. Marlboro shipment volume dropped by 11.4% year over year in the second quarter. The company lost a lot of market share to disposable e-vapor products that evade the regulatory process. Despite that, second-quarter revenue -- net of excise taxes -- declined by just 0.4% year over year. Top-line sales have been declining slowly, but margin expansion has allowed Altria Group's bottom line to grow. Second-quarter operating income climbed by 4.4% year over year. Altria stock has been rising because it looks like the company's other nicotine-delivery products can offset Marlboro losses. Oral tobacco product sales rose by 6% year over year, net of excise taxes. The company could also see a tailwind from increasing oversight of unauthorized nicotine products. Over the past 90 days, the Food and Drug Administration (FDA) has issued 58 warning letters to importers and retailers who sell Geek Bar and similar unauthorized e-vapor products. Altria Group shares offer a 6.7% yield at recent prices, and another dividend raise is probably around the corner. The company raised its dividend payout last August, which was the 59th payout raise announced in 55 years. 2. Healthpeak Properties If there's one thing you can count on, it's rising healthcare needs. Healthpeak Properties is a real estate investment trust (REIT) focused on outpatient medical buildings, laboratories used by drug developers, and retirement communities. Buying shares of this company is an easy way for income-seeking investors to follow the unstoppable healthcare trend. Shares of Healthpeak offer a 6.9% dividend yield at recent prices. Following the COVID-19 pandemic, institutional investors' enthusiasm for biotechnology start-ups fell off a cliff. Healthpeak rents labs to established pharmaceutical companies, start-up biotechs, and everything in between. Lack of demand for lab space from start-ups is a challenge this REIT fought by merging with Physician's Realty, an owner of medical office buildings, last year. Healthpeak acquired Physicians Realty in an all-stock transaction and had to reduce its dividend payment due to the creation of new shares. Investors can reasonably expect significant dividend payout raises in the years ahead. In the second quarter, adjusted funds from operations (FFO), a proxy for earnings used to evaluate REITs, rose to $0.44 per share. This is more than enough to keep up with monthly dividend payments, which are currently set at $0.305 per share per quarter. 3. Ares Capital Ares Capital is a business development company (BDC). These special entities exist to fill the hole left by traditional banks, which hardly ever give direct loans to businesses anymore. Starved for capital, businesses with millions in annual revenue are eager to borrow at interest rates that you might find surprising. During the third quarter, the BDC reported a 10.9% average yield on the debt securities in its portfolio. Shares of Ares Capital offer an 8.4% yield at recent prices. One-time, extra dividend payments in past years make the stock look more unpredictable than it is. Investors seeking a reliable income stream will be glad to know this company's quarterly payout has risen or remained stable since 2009. Lending directly to midsize businesses isn't the easiest banking operation, but Ares Capital has more resources than most of its peers. It's externally managed by a subsidiary of Ares Management, a leader in the alternative investment space, with about $546 billion in assets under management. Ares Capital can boast a highly experienced team of underwriters. Just 1.2% of its loans were on non-accrual status at the end of June. Adding some shares to a diversified portfolio now looks like a great way to build up your passive-income stream. Should you invest $1,000 in Altria Group right now? Before you buy stock in Altria Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Altria Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025


Globe and Mail
5 hours ago
- Globe and Mail
IonQ Partners with Oak Ridge National Laboratory, Demonstrating Quantum Power Grid Optimization Advancements
IonQ (NYSE: IONQ), the leading commercial quantum computing and networking company, announced a new achievement in applying quantum technology to energy grid optimization challenges. Through a collaborative partnership between IonQ, Oak Ridge National Laboratory (ORNL), and the U.S. Department of Energy (DOE), the team has successfully demonstrated that its hybrid quantum-classical computing approach can address the Unit Commitment problem, a critical task for power grid operators. The Unit Commitment problem involves determining the optimal schedule for power generators to meet electricity demand at minimal cost. This task becomes increasingly complex as power systems scale and generate more energy using dispatchable energy resources (e.g. nuclear plants, natural gas, hydroelectric…etc.) and intermittent sources such as solar and wind. IonQ and ORNL developed a hybrid approach that combines IonQ's 36-qubit Forte Enterprise quantum computing with classical computing. Using this hybrid approach, the team found varied solutions for power generation scheduling across 24 time periods and 26 generators. 'This demonstration marks a significant milestone in applying quantum computing to real-world energy challenges. We are proud to be partnering on this ground-breaking work with ORNL and the DOE,' said Niccolo de Masi, CEO of IonQ. 'As our systems scale to thousands and millions of qubits, we expect to solve grid optimization challenges at a scale that classic computing methods cannot match.' The energy sector is increasingly viewed as a key early use case for quantum computing advantages, given its reliance on complex optimization and simulation tasks. According to the U.S. Energy Information Administration, more than 60% of energy used in electricity generation is currently lost, pointing to a significant opportunity for waste reduction through improved planning and computational methods. This research is part of DOE's multi-year GRID-Q project, which brings together national laboratories, academic partners, and private-sector companies. ORNL leads the project, with IonQ as one of only two quantum industry partners tasked with developing scalable quantum algorithms for grid operations. 'This case study, completed by ORNL in partnership with IonQ, demonstrated the feasibility of using an ion-trapped quantum computing device to solve the Unit Commitment problem in the power grid,' said Suman Debnath, who led ORNL's contributions to the project. 'As the quantum device scales, concurrent research is intended to test how the application performance can gain a quantum advantage.' IonQ anticipates that quantum systems with 100 to 200 high-fidelity qubits, which are expected as early as 2026, will be capable of solving grid-scale Unit Commitment problems. The quantum optimization methods demonstrated in this work are applicable to a broad range of industries, including logistics, scheduling, and finance. This latest announcement builds on the established relationship between IonQ and ORNL. The organizations have partnered on several projects including: noise-tolerant methods to help solve the world's hardest optimization problems as well as a novel approach to scalable quantum computing. IonQ is also engaged in a separate $22 million project with EPB of Chattanooga that includes optimizing the energy grid. About IonQ IonQ, Inc. [NYSE: IONQ] is the leading commercial quantum computing, quantum networking and quantum applications company , delivering high-performance systems aimed at solving the world's most complex problems. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results. The company is accelerating its technology roadmap and intends to deliver the world's most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ's advancements in quantum networking also positions the company as a leader in building the quantum internet. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'anticipates,' 'can,' 'eventually,' 'expect,' 'expected,' 'ground-breaking,' 'opportunity,' 'scale,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; IonQ's ability to implement its technical roadmaps, business plans, forecasts, and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ's ability to effectively enter new markets; IonQ's customers deciding or declining to extend contracts into new phases; changes in U.S. government spending or policy that may affect IonQ's customers; and risks associated with U.S. government sales, including availability of funding and provisions that may allow the government to unilaterally terminate or modify contracts for convenience; changes in laws and regulations affecting IonQ's patents; and IonQ's ability to maintain or obtain patent protection for its products and technology, including with sufficient breadth to provide a competitive advantage. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's filings with the U.S. Securities and Exchange Commission, including but not limited to the Company's most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.